S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:MRSN

Mersana Therapeutics - MRSN Stock Forecast, Price & News

$4.13
-0.06 (-1.43%)
(As of 03/24/2023 08:51 PM ET)
Add
Compare
Today's Range
$3.92
$4.16
50-Day Range
$4.13
$7.02
52-Week Range
$2.68
$8.34
Volume
2.54 million shs
Average Volume
1.30 million shs
Market Capitalization
$446.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.71

Mersana Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
256.3% Upside
$14.71 Price Target
Short Interest
Bearish
6.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.63mentions of Mersana Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$164,847 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.97) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

468th out of 995 stocks

Pharmaceutical Preparations Industry

217th out of 482 stocks


MRSN stock logo

About Mersana Therapeutics (NASDAQ:MRSN) Stock

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Mersana Announces FDA Clinical Hold For Phase 1 Trial Of XMT-2056
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Mersana Therapeutics Provides Statement About SVB
Mersana Therapeutics Q4 2022 Earnings Preview
Q4 2022 Mersana Therapeutics Inc Earnings Call
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Company Calendar

Last Earnings
2/28/2023
Today
3/26/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.71
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+256.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-204,210,000.00
Net Margins
-768.26%
Pretax Margin
-768.26%

Debt

Sales & Book Value

Annual Sales
$26.58 million
Book Value
$0.92 per share

Miscellaneous

Free Float
103,273,000
Market Cap
$446.16 million
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Anna ProtopapasAnna Protopapas
    President, Chief Executive Officer & Director
  • Brian DeSchuytner
    Chief Financial Officer & Senior Vice President
  • Timothy B. LowingerTimothy B. Lowinger
    Chief Science & Technology Officer
  • Arvin YangArvin Yang
    Chief Medical Officer & Senior Vice President
  • Alejandra Veronica Carvajal
    Secretary, Chief Legal Officer & Senior VP













MRSN Stock - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month price targets for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $14.71 in the next year. This suggests a possible upside of 256.3% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2023?

Mersana Therapeutics' stock was trading at $5.86 at the start of the year. Since then, MRSN shares have decreased by 29.5% and is now trading at $4.13.
View the best growth stocks for 2023 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The business earned $14.69 million during the quarter, compared to the consensus estimate of $27.85 million. Mersana Therapeutics had a negative trailing twelve-month return on equity of 178.80% and a negative net margin of 768.26%.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.67%), Marshall Wace LLP (2.53%), Braidwell LP (1.87%), Morgan Stanley (1.76%), Geode Capital Management LLC (1.71%) and Silverarc Capital Management LLC (1.14%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Brian Deschuytner, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $4.13.

How much money does Mersana Therapeutics make?

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $446.16 million and generates $26.58 million in revenue each year. The company earns $-204,210,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

The company employs 169 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.

This page (NASDAQ:MRSN) was last updated on 3/27/2023 by MarketBeat.com Staff